InhaTarget Therapeutics develops innovative and targeted dry powders for inhalation (“DPI”) that aim to improve the treatmentsof respiratory diseases, with a particular focus on lung cancer
Capitalizing on its advanced expertise in pulmonary drug delivery (especially in DPI), InhaTarget Therapeutics organizes its activities under two strands:
1. The early development of proprietary products (phase I/II) to be licensed to pharmaceutical partners. InhaTarget therapeutics wants to focus on its core competencies (R&D and clinical proof-of concept) to deliver proven high-quality products to a pharma partner which will be in charge of the conduct of later clinical studies, regulatory approvals and marketing and sales.
Aware of the challenging specificities of the production processes and equipment for high potency compounds, InhaTarget therapeutics may take care of the GMP production of the DPI products (both the samples for clinical trials and the commercial products).
2. The custom development requested by pharmaceutical companies of innovative products for inhalation in different indications (infections, asthma, COPD, etc.), from the pre-formulation to the clinical proof-of-concept.
Using the keen expertise of the team and its specialized equipment, InhaTarget Therapeutics develops, in collaboration with interested pharma partners, innovative DPIs. It does so using particle engineering techniques that are scalable, such as high-pressure homogenization and spray-drying and that, preferably, use approved, endogenous or well-tolerated excipients. The services of InhaTarget therapeutics on lung drug delivery range from in vitro evaluation, to the evaluation of new excipients and/or devices, particle engineering and production methods using novel processes and aerosol formulations, and finally to preclinical studies in different animal models, in vivo evaluation of lung deposition in humans, local and systemic drug bioavailability, and clinical outcomes.
Company Details
- Employees
- 10
- Founded
- -
- Address
- Boulevard Du Triomphe, Ixelles,brussels Region 1050,belgium
- Phone
- +32 (0)2 650 52 54
- in****@****get.com
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- inhatarget.com
- HQ
- Ixelles, Brussels Region
Inhatarget Therapeutics Questions
Inhatarget Therapeutics's helpline number is +32 (0)2 650 52 54
Inhatarget Therapeutics's website is inhatarget.com
Inhatarget Therapeutics's LinkedIn profile is https://be.linkedin.com/company/inhatarget-therapeutics
Inhatarget Therapeutics has
10 employees.
View email and phone details for 10
employees at Inhatarget Therapeutics.
Inhatarget Therapeutics's industry is
Pharmaceutical Manufacturing
Inhatarget Therapeutics's top competitors are
Theratrame,
Amyl Therapeutics,
Univercells,
Conveyxo,
Esobiotec,
Celyad Oncology,
Deuteroncology Nv,
Exo Biologics,
Novadip Biosciences S.a.,
Abscint.
Inhatarget Therapeutics's support email address is info@inhatarget.com
Inhatarget Therapeutics's categories are Pharmaceutical Manufacturing
Inhatarget Therapeutics's founding year is 2018
